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Insulin resistance in non-diabetic 
patients with chronic hepatitis C: 
what does it mean?
Resistência insulínica em portadores de hepatite 
crônica C não diabéticos: qual o significado?
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ABSTRACT 
Objectives: To determine the prevalence of insulin resistance (IR) in non-diabetic patients with 
chronic hepatitis C, and to assess the association between IR, laboratory parameters and histo-
logical findings. Subjects and methods: Eighty-two patients had their serum analyzed for glu-
cose, lipid profile, C-reactive protein (CRP), ferritin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), HOMA-IR, viral load and HCV genotype. Patients with HOMA-IR levels 
> 2.5 were considered as carriers of insulin resistance. Results: IR was observed in 27% of pa-
tients and was associated with age, waist circumference and body mass index. IR patients were 
more likely to have more advanced hepatic fibrosis and necroinflammatory activity, higher 
levels of aminotransferases and liver steatosis than patients without IR. Conclusions: Insulin 
resistance is often present in patients with chronic hepatitis C, and this parameter is associated 
with more advanced HCV-related hepatic fibrosis. Arq Bras Endocrinol Metab. 2011;55(6):412-8
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RESUMO
Objetivos: Em portadores de hepatite crônica C não diabéticos, verificar a prevalência de re-
sistência insulínica (RI) e analisar a associação desta com os parâmetros laboratoriais e histo-
lógicos. Sujeitos e métodos: Foram incluídos no estudo 82 pacientes, e amostras de sangue 
foram coletadas para determinação de glicose, perfil lipídico, alanina aminotransferase (ALT), 
aspartato aminotransferase (AST), ferritina, HOMA-IR, carga viral e genótipo do VHC. HOMA-
-IR superior a 2,5 foi considerado resistência insulínica. Resultados: RI foi observada em 27% 
dos pacientes e foi associada a idade, circunferência abdominal e índice de massa corpórea. 
Quando comparado a pacientes sem RI, aqueles com HOMA-IR superior a 2,5 apresentaram 
graus mais acentuados de fibrose hepática e atividade necroinflamatória, maiores níveis de 
aminotransferases e esteatose hepática mais frequente. Conclusões: É comum a presença de 
RI em portadores de hepatite crônica C e esta se associa com graus mais avançados de fibrose 
hepática induzida pelo vírus da hepatite C. Arq Bras Endocrinol Metab. 2011;55(6):412-8
Descritores
Hepatite crônica C; fibrose hepática; resistência insulínica; HOMA-IR
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is the main cause of death due to liver disease worldwide, and 
is one of the main reasons for liver transplantation. Re-
cent estimates indicate that 2.2% of the world population 
(130 million people) are infected with HCV (1). Data 
from the Brazilian Society of Hepatology obtained from 
Brazilian blood donors have shown a prevalence rate of 
HCV infection equal to 1.1%, with higher rates in the 
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Acute HCV infection is most often asymptomatic; 
50-85% of these patients ultimately develop chronic 
hepatitis (3), and 20%-30% of HCV patients develop 
cirrhosis after 20-30 years of disease (4). In a recent 
study, John-Baptiste and cols., reported that 14.8% of 
the individuals who acquired HCV infection by intrave-
nous drug use developed cirrhosis 20 years after being 
infected (5). The rate of progression to cirrhosis is the 
most important factor in the natural history of HCV in-
fection. Once cirrhosis develops, complications due to 
portal hypertension account for HCV-related morbidi-
ty and mortality. Since most patients with HCV-related 
chronic hepatitis do not develop cirrhosis, it is logical 
to infer that host-related and virus-related factors must 
play a role in the progression to cirrhosis. In a pivotal 
2001 study by Poynard and cols., host-related varia-
bles, such as male sex, age at the time of infection and 
excessive alcohol intake were independently associated 
with progression of HCV-induced liver fibrosis (6). In 
recent years, other factors, such as coinfection with hu-
man immunodeficiency virus (HIV), insulin resistance 
(IR) and hepatic steatosis, have also been linked to pro-
gression of hepatic fibrosis (7-10). In 2003, Hui and 
cols. studied 260 patients with HCV-related chronic 
hepatitis and found that the Homeostasis Model As-
sessment of Insulin Resistance (HOMA-IR), a marker 
of insulin resistance (IR), was independently associated 
with advanced fibrosis (8).
The importance of IR has been increasingly recog-
nized, and its association with the metabolic syndrome 
(MS) – characterized by central obesity, dyslipidemia, 
abnormalities in glycemic control and arterial hyper-
tension (11) – are well established, probably represen-
ting its main pathogenic mechanism. The importance 
of MS has been increasingly recognized in hepatology 
literature. Non-alcoholic fatty liver disease (NAFLD) 
is one of the most common liver diseases in the wes-
tern world. It is considered the hepatic manifestation of 
MS, and is linked to the development of liver cirrhosis 
and hepatocellular carcinoma (12). Because insulin pri-
marily facilitates glucose uptake by muscles, liver, and 
adipose tissue, IR seems to be caused by decreased res-
ponsiveness of these tissues to physiological amounts of 
circulating plasma insulin (13), which may be due to 
genetic predisposition or acquired metabolic disorders, 
chiefly visceral obesity (14).
Patients with chronic liver disease, and cirrhosis 
in particular, are known to be prone to IR. However, 
chronic HCV infection may induce IR, regardless of 
the presence of liver cirrhosis. Hui and cols. demonstra-
ted that patients with chronic HCV hepatitis without 
liver fibrosis had increased levels of insulin, HOMA-IR 
and peptide C compared with metabolically-matched 
healthy individuals (8). Two other studies have indirec-
tly demonstrated the cause-effect relationship between 
chronic HCV infection and IR. Patients with HCV-re-
lated hepatitis who had sustained virological responses 
after antiviral therapy were less likely to develop type 2 
diabetes mellitus (DM2) and glycemic alterations, com-
pared with non-responders (15,16). Although the me-
chanisms underlying the development of IR in patients 
with HCV chronic infection have not been fully eluci-
dated, the following factors have been recently conside-
red: changes in insulin signaling pathways due to viral 
proteins; chronic inflammation with overproduction 
of tumor necrosis factor (TNF) and consequent phos-
phorylation of ISR-1 serine residues, lower expression 
of genes related to glucose metabolism, and degrada-
tion of insulin receptor substrates (17).
Besides having higher rates of progression to liver 
fibrosis, patients with chronic HCV hepatitis and IR 
are less likely to respond to antiviral therapy (9,18-20). 
In Brazil, no studies have determined the rate of IR 
occurrence in chronically HCV-infected populations, 
or the consequence of such association. Thus, we ai-
med at assessing the prevalence rate of IR in an HCV-
-infected population, and the effects of this association 
on laboratory and histological parameters of chronic 
HCV-related hepatitis. Greater knowledge about this 
intriguing relationship and its impact may provide in-
vestigators with strategies to alter the natural history 
of chronic HCV hepatitis and improve the results of 
antiviral therapy.
SUBJECTS AND METHODS 
This was an observational and cross-sectional study, 
with prospective inclusion of data. After approval by 
the Committee of Research Ethics at the University 
Hospital of the Universidade Federal de Juiz de Fora 
(HU-UFJF), informed consent was obtained and pa-
tients were included in the study. Patients with chronic 
HCV hepatitis seen at the HU-UFJF Hepatology Refe-
rence Center were consecutively enrolled, from January 
2010 to June 2011. The eligibility criterion was  chro-
nic HCV infection documented by positive results in 
qualitative HCV-RNA test. Exclusion criteria included: 
previous antiviral treatment, coinfection with hepati-
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tis B virus (HBV) or human immunodeficiency virus 
(HIV I and II), chronic renal disease, type 2 DM, de-
compensated liver cirrhosis, hepatocellular carcinoma, 
and average alcohol intake greater than 20 g ethanol/
day (women) and 40 g ethanol/day (men) during the 
preceding year. 
Enrolled patients underwent clinical assessment 
(history and physical examination) and had blood sam-
ples drawn. The following demographic, epidemiolo-
gical and clinical data were recorded on enrollment: 
gender, age at the time of liver biopsy, cause of HCV 
(blood transfusion; intravenous drug use; sexual inter-
course; indeterminate causes; and other causes, such as 
inhaled drugs, acupuncture or surgery), blood pressu-
re, weight, height, body mass index (BMI) and abdo-
minal circumference. 
Serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyl transpepti-
dase (GGT), albumin and fasting glucose (kinetic me-
thod), cholesterol and triglycerides (colorimetric me-
thod) were carried out with Abbott reagents. DiaSys 
and precipitation were employed for HDL cholesterol 
(HDL-c), and the Friedwald formula was employed for 
LDL cholesterol (LDL-c). The international normali-
zed ratio of prothrombin time (INR) was determined 
with ISI and PT-Fib recombinant reagent and proces-
sed in an ACL 3000 device, with ISI determined by the 
manufacturer. Ferritin was measured using DiaSys rea-
gent and chemiluminescent microparticle immunoassay 
methodology (CMIA). Ultra-sensitive C-reactive pro-
tein (CRP) was determined with immunoturbidimetry. 
Hepatitis C viral load was determined using real-time 
polymerase chain reaction (Abbott HCV Real Time) 
and HCV genotyping (Reverse transcription – polyme-
rase chain reaction / nucleic acid sequencing). Serum 
insulin levels were determined using the microparticle 
enzyme immunoassay (MEIA), Abbott AxSYMR sys-
tem. The level of IR was assessed using HOMA-IR 
(Homeostasis model assessment of insulin resistance), 
calculated as fasting blood glucose [mmol/L] X fas-
ting blood insulin [mil/L] / 22.5). IR was defined as 
HOMA-IR > 2.5. Biochemical analyses were performed 
at the HU-UFJF Central Laboratory; fasting insulin, 
HOMA-IR and ultra-sensitive CRP were performed at 
the Cortes Villela Laboratory – Juiz de Fora – MG; 
molecular biology assays (qualitative HCV-RNA, quan-
titative HCV-RNA, HCV genotyping) were performed 
at the Universidade Federal de Minas Gerais NUPAD 
Laboratory.
 Histopathological assessment included: stage of fi-
brosis and periportal necroinflammatory activity accor-
ding to the Metavir histological score (21), and pre-
sence of steatosis, quantified as follows: up to 5%; 5% 
to 33%; 33% to 66%; and over 66%, according to Brunt 
(22). Patients with any contraindication to liver biopsy, 
but with clinical, laboratory and imaging evidence of 
liver cirrhosis (stage 4 fibrosis) were included. All liver 
biopsies were analyzed by a single pathologist, experien-
ced in liver pathology and blind to patients’ clinical data.
MS was diagnosed according to the criteria of the 
International Federation of Diabetes (IDF), American 
Heart Association (AHA) and National Heart, Lung 
and Blood Institute (23). According to the latter, MS 
was diagnosed by the presence of at least three of the 
following symptoms: systemic arterial blood pressu-
re (BP) > 130 x 85 mmHg; high-density lipoprotein 
(HDL) cholesterol < 40 mg/dL (men) and < 50 mg/
dL (women); triglycerides > 150 mg/dL; fasting blood 
glucose > 100 mg/dL; abdominal circumference > 90 
cm (men) and > 80 cm (women) (levels recommen-
ded by South and Central America populations by the 
International Diabetes Federation). For the analysis 
of the results, patients were allocated to two groups: 
Group I – patients with chronic HCV hepatitis without 
IR, and Group II – patients with chronic HCV hepa-
titis and IR.
Statistical analysis
The SPSS program (15.0 for Windows) was used. Nu-
merical variables were expressed as means ± standard 
deviation, and medians, when appropriate. Categorical 
variables were expressed as absolute (n) and relative 
(%) frequencies. For statistical analysis of the catego-
rical variables, chi-square and Fisher’s exact tests were 
used. For comparison of numerical variables between 
the two groups, Student “t” and Mann-Whitney tests 
were used. Significance level adopted was P less than 
0.05 (α = 5%).
RESULTS
Eighty two patients (mean age of 51 years), 42 (51%) 
men and 40 (49%) women, were included in the stu-
dy. IR and obesity were observed in 22 (27%) and 15 
(18%) of them, respectively (Table 1). Patients with 
chronic HCV hepatitis and IR had greater mean age 
(56.9 ± 10.1 vs. 49.7 ± 12.3; p = 0.03), larger ab-
dominal circumference (97.8 ± 11.9 vs. 87.1 ± 11.1; 
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p = 0.04) and higher BMI (28.1 ± 4.4 vs. 25.4 ± 4.1; p 
= 0.01), compared with individuals without IR (Tables 
1 and 2). Gender, obesity, and systemic arterial hyper-
tension were similar between patients with and without 
IR. MS was present in 24 (29%) patients; 41% in the IR 
group vs. 25% in the group without IR, although the 
difference was not statistically significant (Table 1).
Patients with chronic HCV hepatitis and IR had hi-
gher levels of blood glucose (p = 0.004), fasting insulin 
Table 1. Demographic and anthropometric characteristics of the 82 
patients according to the presence or absence of insulin resistance (IR)
Variables N (%) IR absent(n = 60)
IR present
(n = 22) P
Male 42 (51%) 32 (53%) 10 (45%) NS
Obesity 15 (18%) 10 (17%) 5 (23%) NS
Metabolic syndrome 24 (29%) 15 (25%) 9 (41%) NS
Hypertension 39 (48%) 26 (43%) 13 (59%) NS
Table 2. Clinical and anthropometric data of the 82 patients according to the presence or absence of insulin resistance (IR)
Variables Mean (SD) Min-Max IR absent IR present P
Age (years) 50.7 (12,1) 23 – 79 49.7 (12,3) 56.9 (10.1) 0.03
Abd. circ. (cm) 89.7 (10,7) 59 – 124 87.1 (11,1) 97.8 (11.9) 0.04
Weight (kg) 69.9 (12,6) 40.3 – 108 68.9 (11.7) 72.7 (14.7) NS
Height (meters) 1.64 (0,1) 1.44 – 1.87 1.65 (0.1) 1.61 (0.1) NS
BMI (Kg/m2) 26.1 (4,3) 17.7 – 40.5 25.4 (4.1) 28.1 (4.4) 0.01
SBP (mmHg) 133.1 (19,6) 100-180 128 (16.9) 131.1 (20.9) NS
DBP (mmHg) 85.2 (12,3) 60-120 85 (11.6) 85.7 (14.5) NS
Abd. circ.: abdominal circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 3. Laboratory data of the 82 patients according to the presence or absence of insulin resistance (IR)
Variables  Mean (SD) Min-Max IR absent IR Present P
Fasting glucose 92.1 (12.9) 74-122 87.6 (10.5) 96.8 (12.8) 0. 004
Fasting insulin 8.6 (7.0) 0-38.9 5.4 (3.1) 18.1 (7.1) < 0. 0001
HOMA-IR* 1.5 (1.9) 0-10.9 1.1 (0.7) 4.4 (2.0) < 0. 0001
Triglycerides 108.3 (58.6) 28-385 118.5 (71.3) 118.7 (53.4) NS
Total cholesterol 172.8 (37.7) 77-259 179.6 (31.2) 178 (41.2) NS
HDL-cholesterol 47.9 (14) 21-82 47.5 (14) 43.1 (10.7) NS
PCR 0.29 (1.3) 0.1-6.6 0.6 (0.8) 1.1 (2.1) NS
Ferritin 146.5 (168.6) 18.5-1000 167.9 (136.3) 199.8 (194.3) NS
ALT (x URV)* 1.6 (1.6) 0.2-9.1 1.5 (0.7) 3.0 (2.3) 0.03
AST (x URV) 1.6 (0.9) 0.3-4.7 1.2 (0.6) 2.5 (1.4) < 0.0001
GGT (x URV)* 1.0 (1.4) 0.1-8.1 1.2 (1.4) 1.4 (0.8) 0.03
Albumin 4.2 (0.5) 3.3-5.7 4.3 (0.4) 4.0 (0.6) 0.003
INR* 1.1 (0.3) 1-3.4 1.1 (0.1) 1.2 (0.2) 0.02
Platelets (x1000) 205 (79.9) 71-418 209.8 (72.2) 171.7 (54.0) NS
Viral load (UI/mL)** 2,377,519 256-37,200,000 2,480,319 2,118,353 NS
Genotype 1 61 (77%) 46 (81%) 15 (68%) NS
* Mann Whitney; xURV: times the upper reference value; ** performed in 74 patients.
(p < 0. 0001) and HOMA-IR (p < 0.0001), compared 
with patients without IR (Table 2). Levels of ALT (p 
= 0.03), AST (p < 0. 0001), GGT (p = 0.03) and INR 
(p = 0.02) were significantly higher, and albumin levels 
were significantly lower (p = 0.003) in patients with 
chronic HCV hepatitis and IR. There was no association 
between IR, viral load and HCV genotype. Of the 82 
patients included in the study, only two did not undergo 
liver biopsy because of coagulopathy. They were consi-
dered F4 (grade 4 fibrosis), as mentioned in the inclu-
sion criteria. Thus, 29 (36%) patients had liver fibrosis 
≥ 2, and nine had liver cirrhosis (F4). Patients with IR 
were more likely to have steatosis (p = 0.001), higher 
grades of fibrosis (p = 0.005) and periportal necroin-
flammatory activity (p = 0.04). Furthermore, patients 
with IR had higher rates of advanced liver fibrosis (fibro-
sis ≥ 2; p = 0.007), and a tendency towards higher rates 
of periportal necroinflammatory activity ≥ 2 (p = 0.08).
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carriers, which are responsible for glucose entry in the 
cells, especially GLUT4, one of the main insulin-me-
diated glucose uptake regulators (36). Adipose tissue is 
no longer considered to be merely a lipid storage com-
partment, but an endocrine organ, which can secrete 
interleukin 6, leptin, adiponectin, insulin-like growth 
factor (IGF-1), and other substances that may alter in-
sulin sensitivity (37).
In our sample, IR patients had higher levels of 
blood glucose, fasting insulin and HOMA-IR. Disor-
dered glucose metabolism is certainly the main conse-
quence of IR, supporting the higher prevalence rates of 
DM2 in patients with chronic hepatitis C. The levels of 
total cholesterol, HDL-cholesterol, LDL-cholesterol 
and triglycerides were similar in both groups. The levels 
of ALT, AST and GGT were significantly higher in IR 
patients, which may reflect more severe inflammatory 
injury and the presence of steatosis. IR patients have a 
greater production of inflammatory cytokines, such as 
IL-6, resistin, TNF-alfa and CRP, which may promote 
inflammatory injury to the hepatocytes. Furthermore, 
adiponectin is a potent anti-inflammatory cytokine, and 
IR patients typically have lower levels of this cytokine. 
In this study, we found a higher rate of liver steatosis in 
IR patients, which may also explain the higher levels of 
ALT and AST. Higher levels of GGT have been obser-
ved in subjects with hyperinsulinemia, central obesity 
and hypertension (38). The lower levels of albumin and 
the increased INR in our study likely represent the hi-
gher stage of liver fibrosis observed in this group, and 
the consequent impairment of liver synthetic activity.
We found a significantly higher rate of hepatic stea-
tosis in patients with IR (74%) than in those without IR 
(32%), a statistically significant difference. IR and obe-
sity are likely to activate a cascade of events leading to 
excessive release of free fatty acids from the liver. When 
plasma uptake and “de novo” synthesis of free fatty acids 
overcome hepatocyte ability to oxidize and export the-
se compounds as triglycerides, they accumulate in the 
liver parenchyma, causing steatosis (39). In this study, 
we observed that IR patients had higher levels of HCV-
-induced liver fibrosis, compared with subjects without 
IR. Several international studies have found similar re-
sults (8,10,31). Liver steatosis may have contributed to 
this finding. Steatosis could facilitate the development 
of liver fibrosis by means of oxidative stress resulting 
from the build-up of lipids in the hepatocytes, leading 
to greater secretion of inflammatory cytokines, forma-
tion of oxygen reactive species, and activation of liver 
Table 4. Histological data of the 80 patients according to the presence or 
absence of insulin resistance (IR)
Variables IR absent IR present P 
Steatosis* 33 (42%) 19 (32%) 14 (74%) 0.001
Liver cirrhosis*** 09 (11%) 4 (44%) 5 (56%) NS
Fibrosis (mean ± SD)** 1.34 (1.33) 1.1 (1.2) 2.2 (1.4) 0.005
Fibrosis ≥ 2* 29 (36%) 16 (27%) 13 (62%) 0.004
PPA (mean ± SD)** 1.49 (0.8) 1.4 (0.8) 1.9 (0.9) 0.04
PPA ≥ 2* 36 (46%) 24 (41%) 12 (63%) 0.08
* Chi-square; ** t test; PPA: periportal necroinflammatory activity; *** liver cirrhosis (2 patients 
did not undergo liver biopsy).
DISCUSSION
Epidemiological studies support an association betwe-
en chronic HCV hepatitis and type DM2 as the prima-
ry predisposing factor being insulin resistant (IR) (24-
27). According to Mehta and cols. (2000), subjects 
who are more than 40 years old and have anti-HCV 
antibodies have a 3.77 fold higher risk of developing 
DM2, compared with those who were anti-HCV nega-
tive, matched for gender, BMI and ethnic background 
(27). Although liver cirrhosis (regardless of etiology) 
has been associated with the development of IR and 
DM2, chronic HCV infection is reported to be more 
strongly related with the development of IR than chro-
nic HBV hepatitis (26).
In our study, from 82 patients, 22 (27%) had se-
rum HOMA-IR levels greater than 2.5, which is con-
sistent with IR diagnosis. There is no consensus on IR 
assessment and reference values among HCV carriers 
or even among subjects without liver disease. Serum 
HOMA-IR has been used as an indirect way to measu-
re IR, and correlates well with insulin sensitivity using 
the euglycemic/hyperinsulinemic clamping technique 
(28,29). Cutoff points indicator of IR range from 1.5 
to 3.0 (30-34) in these studies. In a 2009 Brazilian 
study, Geloneze and cols. analyzed 1,203 patients wi-
thout diabetes and without HCV infection (35). They 
reported a HOMA-IR cutoff point of 2.7 for IR diag-
nosis, which is close to the level we used in our study. 
In 2008, Moucari and cols. used a HOMA-IR cutoff 
point of > 3 to diagnose IR and found a 32% rate in 462 
non-diabetic, HCV-positive patients (31).
In our study, IR was associated with age, abdominal 
circumference and BMI. It is known that age, obesi-
ty (particularly centripetal obesity), sedentary lifestyle 
and genetic predisposition are the main causes of IR in 
the general population (36). Advanced age is associa-
ted with lower intracellular concentrations of glucose 
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stellate cells, fundamental to the initiation of liver fibro-
genesis (40,41). In this study, mean necroinflammatory 
activity was higher in IR patients. Again, liver steatosis 
may account for this finding.
In conclusion, this study demonstrated that 27% 
of non-diabetic, HCV-positive patients who were tre-
atment-naïve, had insulin resistance, defined by serum 
HOMA-IR levels > 2.5, associated with age, BMI and 
abdominal circumference. We believe this is the first 
Brazilian study that demonstrates that the occurren-
ce of IR in chronic hepatitis C patients is associated 
with higher inflammatory activity (biochemical and 
histological), advanced liver fibrosis and liver steatosis. 
Our data corroborates information already published 
for European and North American populations. IR, a 
potentially modifiable host-related factor, accelerates 
liver fibrogenesis. Future studies are needed to assess 
whether this strategy is able to reduce HCV-induced 
histological injury when metabolic parameters (IR) in 
HCV-positive patients are normalized.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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